Lenalidomide as second-line therapy for advanced hepatocellular carcinoma (HCC): biomarker exploration

被引：1
|
作者：
Shao, Y-Y. [1 ]
Chen, B-B. [2 ]
Lin, Z-Z. [3 ]
Hsu, C-H. [1 ]
Wang, M-J. [3 ]
Cheng, A-L. [1 ]
Hsu, C. [1 ]
机构：
[1] Natl Taiwan Univ NTU, Grad Inst Oncol, Coll Med, Taipei, Taiwan
[2] Natl Taiwan Univ Hosp, Dept Radiol, Taipei, Taiwan
[3] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw371.99
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
707P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
    Shao, Y. -Y.
    Chen, B. -B.
    Ou, D. -L.
    Lin, Z. -Z.
    Hsu, C. -H.
    Wang, M. -J.
    Cheng, A. -L.
    Hsu, C.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 46 (08) : 722 - 730
  • [2] Immunotherapy versus biologics as second-line therapy in advanced hepatocellular carcinoma (HCC)
    Al-Jumayli, Mohammed
    Hildebrand, Hannah
    Abbasi, Saqib
    Kasi, Anup
    Saeed, Anwaar
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [3] Bevacizumab plus temsirolimus as second-line treatment for advanced hepatocellular carcinoma (HCC)
    Chelis, Leonidas
    Deftereos, Savas
    Xenidis, Nikolaos
    Amarantidis, Kiriakos
    Hamalidou, Eleni Kyrillos
    Dimopoulos, Prokopios
    Michailidis, Prodromos
    Christakidis, Evagelos
    Mimidis, Kostantinos
    Pitsiava, Dimitra
    Karayiannakis, Anastasios
    Kakolyris, Stylianos
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma (HCC)
    McNamara, Mairead Geraldine
    Horgan, Anne M.
    Aspinall, Alex
    Chen, Eric Xueyu
    Burak, Kelly
    Dhani, Neesha C.
    Petronis, Jennifer
    Sinaei, Mehrdad
    Kim, Tae Kyoung
    Rogalla, Patrik
    Bathe, Oliver F.
    Knox, Jennifer J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [5] A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma (HCC).
    McNamara, Mairead Geraldine
    Le, Lisa W.
    Horgan, Anne M.
    Aspinall, Alex
    Burak, Kelly W.
    Dhani, Neesha C.
    Chen, Eric Xueyu
    Sinaei, Mehrdad
    Lo, Glen
    Kim, Tae Kyoung
    Rogalla, Patrik
    Bathe, Oliver F.
    Knox, Jennifer J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] Retrospective review of doxorubicin plus sorafenib as second-line therapy in hepatocellular carcinoma (HCC)
    Abou-Alfa, Ghassan K.
    Ma, Jennifer
    O'Reilly, Eileen Mary
    Gansukh, Bolorsukh
    Chou, Joanne F.
    Capanu, Marinela
    Saltz, Leonard
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [7] Regorafenib as second-line therapy in hepatocellular carcinoma
    Duffy, Austin G.
    Greten, Tim F.
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2017, 14 (03) : 141 - 142
  • [8] Second-Line Therapy for Patients With Hepatocellular Carcinoma
    Frenette, Catherine T.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (12) : 3 - 5
  • [9] Regorafenib as second-line therapy in hepatocellular carcinoma
    Austin G. Duffy
    Tim F. Greten
    Nature Reviews Gastroenterology & Hepatology, 2017, 14 : 141 - 142
  • [10] Cabozantinib as a Second-Line Agent in Advanced Hepatocellular Carcinoma
    Kudo, Masatoshi
    LIVER CANCER, 2018, 7 (02) : 123 - 133
12345